C
Code Biotherapeutics
Developing next-generation gene therapies for patients with rare and prevalent genetic diseases
About Code Biotherapeutics
Code Bio is a cutting-edge biotech startup that is revolutionizing the field of genetic medicine. The company is developing a new class of precision genetic medicines to treat life-threatening diseases. Their proprietary technology, 3DNA®, is a synthetic DNA delivery platform that has been designed to overcome the numerous challenges associated with the delivery of genetic medicines. These challenges include dose-related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, the ability to re-dose, and vector manufacturing complexity.
Code Bio's business model revolves around the development and commercialization of their 3DNA® platform and the genetic medicines it enables. The company is currently advancing an internal pipeline focusing on a variety of diseases, with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). They also have research programs underway targeting the lungs, pancreas, and liver.
The company's target market includes patients suffering from life-threatening diseases that can be treated with genetic medicines. Code Bio also seeks partnerships with other entities to further develop and commercialize their strategic programs that hold promise for genetic diseases.
In terms of revenue generation, Code Bio likely makes money through the licensing of its 3DNA® platform, partnerships with other biotech and pharmaceutical companies, and potentially, the sale of its genetic medicines once they receive regulatory approval.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Lower Gwynedd Township, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 61.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2022 | $75M | $300M | NEA · Hatteras Venture Partners · Amgen Ventures · 4BIO Capital | ↗ |
| SEEDOther financing | Apr 2021 | $10M | $40M | NEA · Cure Duchenne · Takeda Ventures · JDRF T1D Fund | — |
Growth signals
Latest recorded traffic for Code Biotherapeutics is 230 monthly website visits, down 71.3% over the last three months. Code Biotherapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
4BIO Capital
UPMC Enterprises
NEA
Cure Duchenne
Takeda Ventures
JDRF T1D Fund
Series A4 investors entered at this stage
Northpond Ventures
Hatteras Venture Partners
Amgen Ventures
UCB Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Code Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Code Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.